BR112018072264A2 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BR112018072264A2
BR112018072264A2 BR112018072264-2A BR112018072264A BR112018072264A2 BR 112018072264 A2 BR112018072264 A2 BR 112018072264A2 BR 112018072264 A BR112018072264 A BR 112018072264A BR 112018072264 A2 BR112018072264 A2 BR 112018072264A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
pharmaceutical composition
antibody
freeze drying
reconstituted
Prior art date
Application number
BR112018072264-2A
Other languages
English (en)
Inventor
Jeffrey Yates Andrew
Ivo MASSANT Jan
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56320265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018072264(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112018072264A2 publication Critical patent/BR112018072264A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção diz respeito às composições farmacêuticas compreendendo um anticorpo ou um fragmento deste, adequadas para a secagem por congelamento (isto é, liofilização). as composições farmacêuticas, que compreendem um anticorpo ou um fragmento de ligação de antígeno deste; de 1 % a 20 % p/v de sacarose; um aminoácido ou uma mistura de aminoácidos; e tensoativo, são fornecidas como composições farmacêuticas para secagem por congelamento; como composições secadas por congelamento (isto é, liofilizadas) que podem ser reconstituídas em um solvente no hora do uso ou como formulações líquidas reconstituídas prontas para a administração.
BR112018072264-2A 2016-05-12 2017-05-11 composição farmacêutica BR112018072264A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608323.0A GB201608323D0 (en) 2016-05-12 2016-05-12 Pharmaceutical compositions
GB1608323.0 2016-05-12
PCT/EP2017/061261 WO2017194646A1 (en) 2016-05-12 2017-05-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR112018072264A2 true BR112018072264A2 (pt) 2019-02-12

Family

ID=56320265

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072264-2A BR112018072264A2 (pt) 2016-05-12 2017-05-11 composição farmacêutica

Country Status (17)

Country Link
US (1) US11407835B2 (pt)
EP (1) EP3454899B1 (pt)
JP (1) JP7126454B2 (pt)
KR (1) KR102436694B1 (pt)
CN (1) CN109069643A (pt)
AR (1) AR108449A1 (pt)
AU (1) AU2017264553A1 (pt)
BR (1) BR112018072264A2 (pt)
CA (1) CA3022124A1 (pt)
CL (1) CL2018003178A1 (pt)
CO (1) CO2018011733A2 (pt)
EA (1) EA201892446A1 (pt)
GB (1) GB201608323D0 (pt)
IL (1) IL262654A (pt)
MX (1) MX2018013215A (pt)
SG (1) SG11201809229VA (pt)
WO (1) WO2017194646A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
MX2022011248A (es) * 2020-03-11 2022-12-15 Selecta Biosciences Inc Metodos y composiciones relacionados con nanoportadores sinteticos.
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
TW202332471A (zh) 2021-12-01 2023-08-16 比利時商Ｕｃｂ生物製藥公司 調配物
WO2023224112A1 (ja) * 2022-05-20 2023-11-23 株式会社ダイセル 液状医薬組成物
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2004290070A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
AU2007251122B2 (en) * 2006-05-12 2013-01-10 Bharat Biotech International Limited A composition useful as a vaccine
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AU2010263058A1 (en) * 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US8788028B2 (en) 2010-07-28 2014-07-22 Medtronic, Inc. Parasympathetic stimulation to enhance tachyarrhythmia detection
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
KR102031020B1 (ko) * 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP3431104A1 (en) * 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
US20150225479A1 (en) * 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
MX2017004975A (es) 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
CA3022124A1 (en) 2017-11-16
EA201892446A1 (ru) 2019-04-30
CL2018003178A1 (es) 2019-02-01
CO2018011733A2 (es) 2019-02-08
WO2017194646A1 (en) 2017-11-16
JP2019514998A (ja) 2019-06-06
EP3454899A1 (en) 2019-03-20
MX2018013215A (es) 2019-02-21
EP3454899C0 (en) 2024-03-20
JP7126454B2 (ja) 2022-08-26
EP3454899B1 (en) 2024-03-20
AU2017264553A1 (en) 2018-12-13
US11407835B2 (en) 2022-08-09
KR102436694B1 (ko) 2022-08-25
IL262654A (en) 2018-12-31
KR20190008320A (ko) 2019-01-23
RU2018141591A3 (pt) 2021-01-13
CN109069643A (zh) 2018-12-21
RU2018141591A (ru) 2020-06-15
US20200048346A1 (en) 2020-02-13
AR108449A1 (es) 2018-08-22
SG11201809229VA (en) 2018-11-29
GB201608323D0 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
BR112018072264A2 (pt) composição farmacêutica
BR112019009113A2 (pt) formulações de vírus adenoassociado
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
CY1119436T1 (el) Σκευασμα για αντισωμα εναντι- 4 7
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112012012460A2 (pt) "método de liofilização, composições e kits".
DOP2019000250A (es) Composicion farmaceutica que comprende selexipag
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
BR112018071466A2 (pt) novos peptídeos de ligação a cd1d imunogênicos
BR112018014277A2 (pt) formulação, e, método de preparação de uma solução injetável de um axl-adc
BR112014024751A2 (pt) antígenos de clostridium difficile
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
WO2014204854A8 (en) Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
BR112017013269A2 (pt) ?composição farmacêutica líquida?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.